Anika Therapeutics Company Profile (NASDAQ:ANIK)

About Anika Therapeutics

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. Its therapeutic offerings consist of products in the areas, such as Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. It offers products made from HA based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Its orthobiologics products primarily consist of viscosupplementation and regenerative orthopedics products. Its viscosupplementation franchise includes ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: ANIK
  • CUSIP: 03525510
Key Metrics:
  • Previous Close: $46.48
  • 50 Day Moving Average: $47.99
  • 200 Day Moving Average: $47.92
  • 52-Week Range: $30.93 - $54.96
  • Trailing P/E Ratio: 20.41
  • Foreward P/E Ratio: 23.03
  • P/E Growth: 1.60
  • Market Cap: $690.82M
  • Outstanding Shares: 14,777,000
  • Beta: 1.5
Profitability:
  • Net Margins: 33.77%
  • Return on Equity: 17.24%
  • Return on Assets: 15.60%
Debt:
  • Current Ratio: 14.70%
  • Quick Ratio: 13.06%
Additional Links:
Companies Related to Anika Therapeutics:

Analyst Ratings

Consensus Ratings for Anika Therapeutics (NASDAQ:ANIK) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $49.50 (5.88% upside)

Analysts' Ratings History for Anika Therapeutics (NASDAQ:ANIK)
Show:
DateFirmActionRatingPrice TargetDetails
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/26/2016Barrington ResearchBoost Price TargetOutperform$45.00 -> $49.00View Rating Details
8/27/2015First AnalysisInitiated CoverageEqual -> Equal WeightView Rating Details
11/12/2014Singular ResearchLower Price TargetBUY -> Buy$51.50 -> $45.50View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Anika Therapeutics (NASDAQ:ANIK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2016        
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/30/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)
Current Year EPS Consensus Estimate: $1.96 EPS
Next Year EPS Consensus Estimate: $2.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.19$0.25$0.22
Q2 20162$0.38$0.47$0.43
Q3 20162$0.46$0.47$0.47
Q4 20162$0.47$0.48$0.48
Q1 20171$0.48$0.48$0.48
Q2 20171$0.48$0.48$0.48
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Anika Therapeutics (NASDAQ:ANIK)
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 77.85%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.90View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
DateHeadline
nasdaq.com logoAcelRx (ACRX) Initiates Phase III IAP312 Study on Zalviso - Nasdaq (NASDAQ:ANIK)
www.nasdaq.com - September 28 at 3:28 PM
finance.yahoo.com logoJazz Pharma Closes Enrollment in OSA Drug Phase III Trial (NASDAQ:ANIK)
finance.yahoo.com - September 28 at 3:28 PM
nasdaq.com logoIonis/Biogen Complete Nusinersen NDA Submission in U.S. - Nasdaq (NASDAQ:ANIK)
www.nasdaq.com - September 27 at 3:31 PM
openpr.com logoViscosupplementation Market Revenue to Reach US$ 327.2 Mn by 2026 (NASDAQ:ANIK)
www.openpr.com - September 27 at 5:26 AM
investornewswire.com logoCan Shares Of Anika Therapeutics Inc. (NASDAQ:ANIK) Hit $60? - Investor Newswire (NASDAQ:ANIK)
www.investornewswire.com - September 26 at 8:29 PM
investorplace.com logo13 Health Care Equipment & Supplies Stocks to Buy Now ... - Investorplace.com (NASDAQ:ANIK)
investorplace.com - September 26 at 3:29 PM
capitalcube.com logoETF’s with exposure to Anika Therapeutics, Inc. : September 26, 2016 (NASDAQ:ANIK)
www.capitalcube.com - September 26 at 3:29 PM
News IconResearch Report and Overview on Non-Surgical Bio-Implants Market, 2016-2026 (NASDAQ:ANIK)
www.emailwire.com - September 24 at 8:49 AM
businesswire.com logoAnika Announces Data Presentations on HYALOFAST Hyaluronic Acid-Based Scaffold at 2016 World Congress of the ... - Business Wire (press release) (NASDAQ:ANIK)
www.businesswire.com - September 23 at 8:20 AM
investornewswire.com logoAnika Therapeutics Inc. (NASDAQ:ANIK)'s Expectation Of $119.39 In Sales - Investor Newswire (NASDAQ:ANIK)
www.investornewswire.com - September 23 at 8:20 AM
finance.yahoo.com logoAnika Announces Data Presentations on HYALOFAST Hyaluronic Acid-Based Scaffold at 2016 World Congress of the International Cartilage Repair Society (NASDAQ:ANIK)
finance.yahoo.com - September 23 at 8:20 AM
finance.yahoo.com logoHyaluronic Acid Market Analysis by Product, by Application, by Raw ... - Yahoo Finance (NASDAQ:ANIK)
finance.yahoo.com - September 22 at 9:23 AM
finance.yahoo.com logoGilead to Stop GS-5745 Development for Ulcerative Colitis - Yahoo Finance (NASDAQ:ANIK)
finance.yahoo.com - September 22 at 9:23 AM
finance.yahoo.com logoRegeneron, Teva Collaborate to Develop Chronic Pain Drug (NASDAQ:ANIK)
finance.yahoo.com - September 21 at 4:25 PM
prnewswire.com logoHyaluronic Acid Market Analysis by Product, by Application, by Raw Materials, and Segment Forecasts to 2024 (NASDAQ:ANIK)
www.prnewswire.com - September 21 at 4:25 PM
finance.yahoo.com logoVical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study (NASDAQ:ANIK)
finance.yahoo.com - September 21 at 9:14 AM
investornewswire.com logoShares Of Anika Therapeutics Inc. (NASDAQ:ANIK) Expected To Hit $60 - Investor Newswire (NASDAQ:ANIK)
www.investornewswire.com - September 20 at 3:31 PM
News IconShares Have Ticked Up Over the Last Five Trading Sessions: Anika Therapeutics Inc. (NASDAQ:ANIK) - Post News (NASDAQ:ANIK)
www.kentuckypostnews.com - September 20 at 3:31 PM
finance.yahoo.com logoCelgene Presents Efficacy & Safety Phase II Ozanimod Data (NASDAQ:ANIK)
finance.yahoo.com - September 20 at 9:26 AM
News IconStock Down Over the Last Quarter: Anika Therapeutics Inc ... - Post News (NASDAQ:ANIK)
www.kentuckypostnews.com - September 18 at 8:18 AM
News IconGlobal Hemostats Market 2016 by Manufacturers, Regions, Type and Application, Forecast to 2021 (NASDAQ:ANIK)
www.marketingdive.com - September 17 at 3:30 PM
News IconWestern Europe has been Estimated to Dominate the Europe Viscosupplementation Market (NASDAQ:ANIK)
www.artipot.com - September 17 at 8:19 AM
News IconRegenerative Medicine Market Will be Worth 6.4 Billion USD by 2019; Wide Ranging Application Area of Regenerative Medicines I... (NASDAQ:ANIK)
www.advfn.com - September 17 at 8:19 AM
nasdaq.com logoTeva/Intel Tie up for Huntington's Disease Technology Platform - Nasdaq (NASDAQ:ANIK)
www.nasdaq.com - September 16 at 3:30 PM
finance.yahoo.com logoAerie (AERI) Stock Up on Positive Phase III Data on Roclatan - Yahoo Finance (NASDAQ:ANIK)
finance.yahoo.com - September 16 at 12:11 PM
nasdaq.com logoGlaxo (GSK) Publishes Phase III Data on Shingles Vaccine - Nasdaq (NASDAQ:ANIK)
www.nasdaq.com - September 15 at 8:39 PM
finance.yahoo.com logoAerie (AERI) Stock Up on Positive Phase III Data on Roclatan (NASDAQ:ANIK)
finance.yahoo.com - September 15 at 12:25 PM
News IconRegenerative Medicine Market: Global Industry Analysis and Opportunity Assessment, 2015-2019 (NASDAQ:ANIK)
www.kait8.com - September 14 at 8:46 PM
News IconHyaluronic Acid Market is Expected to Reach $13.4 Billion, Globally, by 2024 – Hexa Reports (NASDAQ:ANIK)
www.abnewswire.com - September 14 at 8:46 PM
nasdaq.com logoWill Bayer (BAYRY) Raise its Monsanto Buyout Offer Again? - Nasdaq (NASDAQ:ANIK)
www.nasdaq.com - September 14 at 3:32 PM
nasdaq.com logoWill Bayer (BAYRY) Raise its Monsanto Buyout Offer Again? - Nasdaq (NASDAQ:ANIK)
www.nasdaq.com - September 14 at 3:32 PM
News IconHealthinvest Partners Ab Increased Anika Therapeutics INC (NASDAQ:ANIK) by $4.91 Million as Shares Rose - Frisco Fastball (NASDAQ:ANIK)
friscofastball.com - September 14 at 8:31 AM
finance.yahoo.com logoSanofi (SNY) forms Diabetes Joint Venture with Alphabet - Yahoo Finance (NASDAQ:ANIK)
finance.yahoo.com - September 13 at 8:21 AM
investornewswire.com logoCan Shares Of Anika Therapeutics Inc. (NASDAQ:ANIK) Hit $60 - Investor Newswire (NASDAQ:ANIK)
www.investornewswire.com - September 13 at 8:21 AM
finance.yahoo.com logoLexicon Hits 52-Week High on Positive Type I Diabetes Data (NASDAQ:ANIK)
finance.yahoo.com - September 12 at 3:31 PM
sbwire.com logoRegenerative Medicine Market - Next Big Thing in Medical Science That Aims to Regenerate, Repair or Replace Damaged Tissue and Organs (NASDAQ:ANIK)
www.sbwire.com - September 12 at 3:31 PM
zacks.com logoSanofi (SNY) forms Diabetes Joint Venture with Alphabet (NASDAQ:ANIK)
www.zacks.com - September 12 at 8:18 AM
openpr.com logoRegenerative Medicine Market : Bright Future for Medical Science That Aims To Regenerate, Repair Or Replace Damaged Tissue And Organs (NASDAQ:ANIK)
www.openpr.com - September 11 at 8:16 AM
investornewswire.com logoAnika Therapeutics Inc. (NASDAQ:ANIK) Expects Sales Of $119.39 - Investor Newswire (NASDAQ:ANIK)
www.investornewswire.com - September 9 at 8:19 AM
realistinvestor.com logoA Price Target Of $58.5 Is Set By Research Analysts For Anika Therapeutics Inc. (NASDAQ:ANIK) - RealistInvestor.com (NASDAQ:ANIK)
www.realistinvestor.com - September 8 at 3:29 PM
sbwire.com logoHyaluronic Acid Product Market: Segments, Opportunity, Growth and Forecast by End-Use Industry 2021 (NASDAQ:ANIK)
www.sbwire.com - September 7 at 12:28 PM
News IconGlobal Hemostats Consumption Market 2016: Ethicon, Inc., SURGICEL? Original Absorbable Hemostat, Pfizer, Inc. Revenue and Gross Margin (NASDAQ:ANIK)
www.medgadget.com - September 7 at 12:28 PM
finance.yahoo.com logoBioMarin's (BMRN) Brineura Review Period Extended by FDA (NASDAQ:ANIK)
finance.yahoo.com - September 7 at 12:27 PM
finance.yahoo.com logoBristol-Myers' Orencia Gains EU Approval for Expanded Use (NASDAQ:ANIK)
finance.yahoo.com - September 7 at 12:27 PM
News IconReport Published: "Adhesion Barrier Market - Global Forecast to 2021" (NASDAQ:ANIK)
reports.pr-inside.com - September 6 at 3:29 PM
newsmaker.com.au logoHyaluronic Acid Market set to reach USD Around 10.90 Billion by 2020 (NASDAQ:ANIK)
www.newsmaker.com.au - September 6 at 3:29 PM
News IconBayer (BAYRY) Raises Offer to Purchase Monsanto Yet Again (NASDAQ:ANIK)
www.yahoo.com - September 6 at 3:29 PM
News IconGlobal Hyaluronic Acid Market to Progress at 9% CAGR from 2015 to 2020 (NASDAQ:ANIK)
qwtjlive.com - September 5 at 8:23 AM
News IconStock Struggling for the Quarter: Anika Therapeutics Inc. (NASDAQ:ANIK) - Post News (NASDAQ:ANIK)
www.kentuckypostnews.com - September 4 at 8:17 AM
kcregister.com logoTop Stories: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), Anika Therapeutics Inc. (NASDAQ:ANIK), Caterpillar Inc ... - KC Register (NASDAQ:ANIK)
www.kcregister.com - September 2 at 3:31 PM

Social

Anika Therapeutics (NASDAQ:ANIK) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff